Head-to-head evidence
semaglutide vs VRB-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: October 2026 · NCT07505303 (registry estimate)
VRB-101
Developed by Verdiva Bio
NCT07281937 · Phase 2 · completed
The trial randomly assigns participants to VRB-101 or a matching placebo and keeps participants, care providers and assessors all blinded, using percent body weight change, a standard measure for obesity drugs, as its main result. Results have not been posted yet, so whether the weight-loss difference was statistically meaningful is not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: November 2026 · NCT07553299 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: semaglutide's landscape · VRB-101's landscape